Genomic profiling of pediatric ALK-positive anaplastic large cell lymphoma: A children's cancer and leukaemia group study

Genes Chromosomes and Cancer

Volumn 48, Issue 11, 2009, Pages 1018-1026

  Youssif, Catrin ^a   Goldenbogen, Jan ^a   Hamoudi, Rifat ^a   Carreras, Joaquim ^a   Viskaduraki, Maria ^b   Cui, Yu Xin ^a   Bacon, Chris M ^c   Burke, G A Amos ^d   Turner, Suzanne D ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CHROMOSOME PROTEIN; DEOXYRIBONUCLEOPROTEIN; HOMEODOMAIN PROTEIN; PROTEIN BIRC 5; PROTEIN DDB 1; PROTEIN HOXB 1; UNCLASSIFIED DRUG;

ARTICLE; BIOPSY; CANCER SURVIVAL; CHILDHOOD CANCER; CHROMOSOME 1; CHROMOSOME 11; CHROMOSOME 14; CHROMOSOME 17; CHROMOSOME 4; CHROMOSOME 5; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DNA ISOLATION; GENE MUTATION; GENOMICS; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; LEUKEMIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; COMPARATIVE GENOMIC HYBRIDIZATION; DNA-BINDING PROTEINS; GENE DELETION; HOMEODOMAIN PROTEINS; HUMANS; KAPLAN-MEIERS ESTIMATE; LYMPHOMA, LARGE-CELL, ANAPLASTIC; MARKOV CHAINS; MICROTUBULE-ASSOCIATED PROTEINS; MUTAGENESIS, INSERTIONAL; PROTEIN-TYROSINE KINASES; REPRODUCIBILITY OF RESULTS; STATISTICS, NONPARAMETRIC;

EID: 70349320286     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20701     Document Type: Article

References (32)

1. Argiropoulos B, Humphries RK. 2007. Hox genes in hematopoiesis and leukemogenesis. Oncogene 26:6766-6776.
2. Bai RY, Dieter P, Peschel C, Morris SW, Duyster J. 1998. Nucleophosmin- anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity. Mol Cell Biol 18:6951-6961. (Pubitemid 28533016)
3. Bai RY, Ouyang T, Miething C, Morris SW, Peschel C, Duyster J. 2000. Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway. Blood 96:4319-4327.
4. Brugieres L, Le Deley MC, Rosolen A, Williams D, Horibe K, Wrobel G, Mann G, Zsiros J, Uyttebroeck A, Marky I, Lamant L, Reiter A. 2009. Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: Results of a randomized trial of the EICNHL Group. J Clin Oncol 27:897-903.
5. Care A, Testa U, Bassani A, Tritarelli E, Montesoro E, Samoggia P, Cianetti L, Peschle C. 1994. Coordinate expression and proliferative role of HOXB genes in activated adult T lymphocytes. Mol Cell Biol 14:4872-4877. (Pubitemid 24196836)
6. Chanudet E, Ye H, Ferry J, Bacon CM, Adam P, Muller-Hermelink HK, Radford J, Pileri SA, Ichimura K, Collins VP, Hamoudi RA, Nicholson AG, Wotherspoon AC, Isaacson PG, Du MQ. 2009. A20 deletion is associated with copy number gain at the TNFA/B/C locus and occurs preferentially in translocation- negative MALT lymphoma of the ocular adnexa and salivary glands. J Pathol 217:420-430.
7. Chiarle R, Gong JZ, Guasparri I, Pesci A, Cai J, Liu J, Simmons WJ, Dhall G, Howes J, Piva R, Inghirami G. 2003. NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. Blood 101:1919-1927. (Pubitemid 36237594)
8. Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G. 2008. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 8:11-23.
9. Chou WC, Su IJ, Tien HF, Liang DC, Wang CH, Chang YC, Cheng AL. 1996. Clinicopathologic, cytogenetic, and molecular studies of 13 Chinese Patients with Ki-1 anaplastic large cell lymphoma. Special emphasis on the tumor response to 13-cis retinoic acid. Cancer 78:1805-1812.
10. Cools J, Wlodarska I, Somers R, Mentens N, Pedeutour F, Maes B, De Wolf-Peeters C, Pauwels P, Hagemeijer A, Marynen P. 2002. Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor. Genes Chromosomes Cancer 34:354-362. (Pubitemid 34787456)
11. Cui YX, Kerby A, McDuff FK, Ye H, Turner SD. 2009. NPMALK inhibits the p53 tumor suppressor pathway in an MDM2 and JNK-dependent manner. Blood 113:5217-5227.
12. Fujimoto J, Shiota M, Iwahara T, Seki N, Satoh H, Mori S, Yamamoto T. 1996. Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5). Proc Natl Acad Sci USA 93:4181-4186. (Pubitemid 26146730)
13. Johnson NA, Hamoudi RA, Ichimura K, Liu L, Pearson DM, Collins VP, Du MQ. 2006. Application of array CGH on archival formalin-fixed paraffin-embedded tissues including small numbers of microdissected cells. Lab Invest 86:968-978. (Pubitemid 44268171)
14. Liang X, Meech SJ, Odom LF, Bitter MA, Ryder JW, Hunger SP, Lovell MA, Meltesen L, Wei Q, Williams SA, Hutchinson RN, McGavran L. 2004. Assessment of t(2;5)(p23;q35) translocation and variants in pediatric ALK+ anaplastic large cell lymphoma. Am J Clin Pathol 121:496-506. (Pubitemid 38392957)
15. McCabe MG, Ichimura K, Liu L, Plant K, Backlund LM, Pearson DM, Collins VP. 2006. High-resolution array-based comparative genomic hybridization of medulloblastomas and supratentorial primitive neuroectodermal tumors. J Neuropathol Exp Neurol 65:549-561. (Pubitemid 44288939)
16. Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL, Look AT. 1994. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 263:1281-1284.
17. Nasr MR, Laver JH, Chang M, Hutchison RE. 2007. Expression of anaplastic lymphoma kinase, tyrosine-phosphorylated STAT3, and associated factors in pediatric anaplastic large cell lymphoma: A report from the children's oncology group. Am J Clin Pathol 127:770-778.
18. Onciu M, Behm FG, Raimondi SC, Moore S, Harwood EL, Pui CH, Sandlund JT. 2003. ALK-positive anaplastic large cell lymphoma with leukemic peripheral blood involvement is a clinicopathologic entity with an unfavorable prognosis. Report of three cases and review of the literature. Am J Clin Pathol 120:617-625. (Pubitemid 37186056)
19. Pittaluga S, Wlodarska I, Pulford K, Campo E, Morris SW, Van den Berghe H, De Wolf-Peeters C. 1997. The monoclonal antibody ALK1 identifies a distinct morphological subtype of anaplastic large cell lymphoma associated with 2p23/ALK rearrangements. Am J Pathol 151:343-351. (Pubitemid 27330055)
20. Piva R, Pellegrino E, Mattioli M, Agnelli L, Lombardi L, Boccalatte F, Costa G, Ruggeri BA, Cheng M, Chiarle R, Palestro G, Neri A, Inghirami G. 2006. Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes. J Clin Invest 116:3171-3182. (Pubitemid 44878631)
21. Rosenwald A, Ott G, Pulford K, Katzenberger T, Kuhl J, Kalla J, Ott MM, Mason DY, Muller-Hermelink HK. 1999. t(1;2)(q21;p23) and t(2;3)(p23;q21): Two novel variant translocations of the t(2;5)(p23;q35) in anaplastic large cell lymphoma. Blood 94:362-364. (Pubitemid 29300170)
22. Salaverria I, Bea S, Lopez-Guillermo A, Lespinet V, Pinyol M, Burkhardt B, Lamant L, Zettl A, Horsman D, Gascoyne R, Ott G, Siebert R, Delsol G, Campo E. 2008. Genomic profiling reveals different genetic aberrations in systemic ALK-positive and ALK-negative anaplastic large cell lymphomas. Br J Haematol 140:516-526. (Pubitemid 351230071)
23. Schlette EJ, Medeiros LJ, Goy A, Lai R, Rassidakis GZ. 2004. Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma. J Clin Oncol 22:1682-1688. (Pubitemid 41079807)
24. Turner SD, Alexander DR. 2005. What have we learnt from mouse models of NPM-ALK-induced lymphomagenesis? Leukemia 19:1128-1134.
25. Turner SD, Alexander DR. 2006. Fusion tyrosine kinase mediated signalling pathways in the transformation of haematopoietic cells. Leukemia 20:572-582.
26. Turner SD, Tooze R, Maclennan K, Alexander DR. 2003. Vavpromoter regulated oncogenic fusion protein NPM-ALK in transgenic mice causes B-cell lymphomas with hyperactive Jun kinase. Oncogene 22:7750-7761. (Pubitemid 37485534)
27. Turner SD, Merz H, Yeung D, Alexander DR. 2006. CD2 promoter regulated nucleophosmin-anaplastic lymphoma kinase in transgenic mice causes B lymphoid malignancy. Anticancer Res 26:3275-3279. (Pubitemid 44701496)
28. Turner SD, Yeung D, Hadfield K, Cook SJ, Alexander DR. 2007. The NPM-ALK tyrosine kinase mimics TCR signalling pathways, inducing NFAT and AP-1 by RAS-dependent mechanisms. Cell Signal 19:740-747. (Pubitemid 46298800)
29. van Dongen JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M, Lavender FL, Delabesse E, Davi F, Schuuring E, Garcia- Sanz R, van Krieken JH, Droese J, Gonzalez D, Bastard C, White HE, Spaargaren M, Gonzalez M, Parreira A, Smith JL, Morgan GJ, Kneba M, Macintyre EA. 2003. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 concerted action BMH4-CT98-3936. Leukemia 17:2257-2317. (Pubitemid 38072572)
30. Whitney J. 1997. Testing for differences with the nonparametric Mann-Whitney U test. J Wound Ostomy Continence Nurs 24:12.
31. Zamo A, Chiarle R, Piva R, Howes J, Fan Y, Chilosi M, Levy DE, Inghirami G. 2002. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene 21:1038-1047. (Pubitemid 34174516)
32. Zhang Q, Raghunath PN, Xue L, Majewski M, Carpentieri DF, Odum N, Morris S, Skorski T, Wasik MA. 2002. Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinasepositive T/null-cell lymphoma. J Immunol 168:466-474. (Pubitemid 34014150)